Fosphenytoin
| Evidence Level: L5 | Predicted Indications: 7 |
Table of Contents
Fosphenytoin: From Seizure Control to Conjunctivitis
One-Sentence Summary
Fosphenytoin is an injectable prodrug of phenytoin, an anticonvulsant. The approved-indication text was not supplied in the data, so seizure use is inferred from its drug class. The TxGNN model predicts it may be effective for conjunctivitis, but there are 0 clinical trials and 0 publications supporting this prediction, so it rests on the model score alone.
Quick Overview
| Item | Content |
|---|---|
| Predicted New Indication | Conjunctivitis |
| TxGNN Prediction Score | 99.36% |
| Evidence Level | L5 (model prediction only) |
| US Market Status | ✓ Marketed |
| Number of NDAs | 16 (the listed authorizations are ANDAs) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data is not available in the supplied data. Fosphenytoin is a prodrug of phenytoin, a voltage-gated sodium channel blocker that dampens neuronal excitability. That is a plausible basis for seizure control.
The mechanism does not support this prediction. Nothing in the supplied data connects sodium channel blockade to conjunctival inflammation, which is typically infectious or allergic in origin. The high score (0.994) is a statistical output of the knowledge graph. The model ranks this pair 14,424th overall, and no trial or publication backs it.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
The supplied records give no approved-indication text, so that column is omitted.
| Authorization Number | Product Name | Dosage Form | Manufacturer |
|---|---|---|---|
| ANDA214926 | Fosphenytoin sodium | Injection, solution | Glenmark Pharmaceuticals Inc., USA |
| ANDA078765 | Fosphenytoin Sodium | Injection, solution | West-Ward Pharmaceuticals Corp |
| ANDA077989 | Fosphenytoin Sodium | Injection | Hikma Pharmaceuticals USA Inc. |
| ANDA078476 | Fosphenytoin Sodium | Injection | Amneal Pharmaceuticals LLC |
| ANDA214926 | Fosphenytoin Sodium | Injection, solution | Sagent Pharmaceuticals |
All listed forms are injectable. The data shows the same number (ANDA214926) under two manufacturers.
Safety Considerations
Please refer to the package insert for safety information. No drug interaction records were found in the queried source.
Conclusion and Next Steps
Decision: Hold
Rationale: The conjunctivitis prediction has no supporting trials or literature, and no mechanistic link is apparent. It should not be pursued on the model score alone.
Among the other predictions, only manic bipolar affective disorder (score 99.18%) has any supporting literature. That is one human study of IV fosphenytoin in acute mania (PMID 12716241, J Clin Psychiatry, 2003). Its design and results could not be verified from the supplied abstract, so the provisional L3 grade could change. It is a better-supported research question than conjunctivitis.
To proceed, the following is needed:
- Package insert warnings and contraindications (currently blocking safety screening)
- Mechanism-of-action data from DrugBank
- A literature search focused on fosphenytoin or phenytoin in conjunctivitis
- If the team wants a stronger lead, full-text review of PMID 12716241 to confirm study design and outcomes
This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before any use.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.